A review on pain‐relieving activity of berberine

Mahmoud Hashemzaei,Ramin Rezaee
DOI: https://doi.org/10.1002/ptr.6984
IF: 6.388
2020-12-19
Phytotherapy Research
Abstract:<p>As isoquinoline alkaloid naturally occurs in <i>Coptis</i> and <i>Berberis</i> species, berberine (BER) has shown anti‐oxidant, anti‐tumour, anti‐bacterial and hepatoprotective activities and beneficial effects against digestive, cardiovascular and neurological conditions. Also, BER antiinflammatory, pain‐relieving and anti‐cholinesterase activities were widely studied. The present overview discusses the analgesic effects of BER. Based on the literature, BER exerted pain‐relieving activity against diabetic and chemotherapy‐induced neuropathy, and sciatic nerve injury‐induced pain via down‐regulation of transient receptor potential vanilloid 1, suppression of NF‐κB and modulation of μ and δ opioid receptors. Besides, BER could repress inflammatory markers tumour necrosis factor‐α, interleukin‐6 and IL‐1β, as well as prostaglandin E2, inducible nitric oxide synthase and cyclooxygenase‐2. The modulatory effects of BER on dopamine and <i>N</i>‐methyl <span class="smallCaps">d</span>‐aspartate systems were also noted. Moreover, BER could induce Nrf2 expression but inhibits p38‐MAPK and STAT3 phosphorylation. Noteworthy, anti‐cholinesterase activity, which may potentially contribute to BER analgesic properties, warrants particular attention.</p>
pharmacology & pharmacy,chemistry, medicinal
What problem does this paper attempt to address?